Analysts’ updated eps estimates for Friday, October 13th:

AAR Corp. (NYSE:AIR) had its hold rating reaffirmed by analysts at Canaccord Genuity. They currently have a $40.00 price target on the stock.

Salesforce.com (NYSE:CRM) was upgraded by analysts at Vetr from a strong sell rating to a sell rating. Vetr currently has $90.51 price target on the stock.

DLH Holdings Corp. (NASDAQ:DLHC) had its buy rating reiterated by analysts at Canaccord Genuity. They currently have a $7.00 price target on the stock.

Esterline Technologies Corporation (NYSE:ESL) had its hold rating reiterated by analysts at Canaccord Genuity.

Ford Motor (NYSE:F) was upgraded by analysts at Vetr from a hold rating to a buy rating. Vetr currently has $13.24 price target on the stock.

Gilead Sciences (NASDAQ:GILD) was upgraded by analysts at Vetr from a buy rating to a strong-buy rating. The firm currently has $91.98 price target on the stock.

Johnson & Johnson (NYSE:JNJ) was downgraded by analysts at Vetr from a hold rating to a sell rating. Vetr currently has $129.62 target price on the stock.

Altria Group (NYSE:MO) was downgraded by analysts at Vetr from a strong-buy rating to a buy rating. The firm currently has $71.89 target price on the stock.

Spark Therapeutics (NASDAQ:ONCE) had its buy rating reaffirmed by analysts at Chardan Capital. The firm currently has a $100.00 price target on the stock. The analysts wrote, “We also see it as a important positive on Spark corporate governance that, e.g. during the panel, Spark provided caution to the panel attendees when panelists seemed interested in the potential for Luxturna re-treatment to further improve vision by treating more of the retina. (Spark noted that the company had not yet generated such data and responsibly urged caution.) After the unanimous backing of the panel, Luxturna, which has a PDUFA date of 12 January 2018, could achieve a number of firsts if approved, i.e.””

Snap (NYSE:SNAP) was upgraded by analysts at Vetr from a strong sell rating to a hold rating. The firm currently has $16.13 target price on the stock.

AT&T (NYSE:T) was downgraded by analysts at Vetr from a buy rating to a hold rating. They currently have $39.67 price target on the stock.

Tesla (NASDAQ:TSLA) was upgraded by analysts at Vetr from a strong sell rating to a sell rating. They currently have $320.97 target price on the stock.

Meridian Bioscience (NASDAQ:VIVO) had its hold rating reissued by analysts at Canaccord Genuity. Canaccord Genuity currently has a $14.00 price target on the stock.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) was downgraded by analysts at Vetr from a strong-buy rating to a hold rating. They currently have $14.26 price target on the stock.

Receive News & Ratings for AAR Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AAR Corp and related companies with MarketBeat.com's FREE daily email newsletter.